Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Abnormal Returns
16%
Active Ingredients
25%
Behavioral Biases
50%
Common Structure
16%
Drug Approval
25%
Drug Competition
100%
Drug Markets
45%
Drug Response
50%
Drug Shortages
50%
Entry Decision
35%
Financial Risk
16%
Firm Experience
16%
Firm Risk
50%
Focal Firm
50%
Generic Competition
25%
Generic Drugs
100%
Generic Entry
60%
Government Accountability Office
50%
Hesitancy
20%
Idiosyncratic Risk
33%
Instrumental Analysis
20%
Lab Experiment
50%
Linkage Data
16%
Manufacturing Barriers
100%
Manufacturing Complexity
70%
Market Concentration
35%
Multinational Corporations
16%
Multiple Determinants
35%
Network Structure
16%
Number of Firms
35%
Pharmaceutical Industry
35%
Plant Inspection
20%
Policy Simulation
35%
Pricing Decision
25%
Process Optimization
16%
Regulatory Barriers
100%
Regulatory Environment
35%
Response to Food
50%
Review Process
25%
Review Time
25%
Risk Events
16%
Risk Level
16%
Risk Propagation
33%
Risk Supplier
50%
Shortage Risk
40%
Structural Network Properties
16%
Supply Chain
16%
Supply Chain Relationships
16%
Supply Network
33%
Supply Network Structure
50%
Social Sciences
Diseases
25%
Econometrics
25%
Event Study
12%
Financial Risk
12%
Instrumental Variable
50%
Likelihood
25%
Market Concentration
25%
Official Report
25%
Pharmaceutical Industry
25%
Portfolio Selection
12%
Pricing
50%
Public Health
25%
Sales
7%
Structural Model
50%
Supply Chain Management
37%
Supply Chain Relationship
12%
Supply Chain Risk
25%
Supply Network
50%
Transnational Corporation
12%
U.S. Congress
25%
